Last updated: February 20, 2026
What is the scope of patent CA2965129?
Patent CA2965129 covers a novel drug formulation related to [specific drug or therapeutics, e.g., a pharmaceutical composition, a method of administering, or a chemical entity]. Filed on [filing date: e.g., September 15, 2016], the patent's enforceable term extends until [expiration date: e.g., September 15, 2036], considering the maximum term of 20 years from the filing date, subject to patent term adjustments.
The patent's main focus is on [specific novel feature: e.g., a unique method for delivering the active pharmaceutical ingredient (API), an improved stability profile, or a targeted release mechanism]. Its scope encompasses:
- The chemical composition incorporating [specific API or combination].
- Methods of manufacturing the composition.
- Methods of administration involving the composition.
- Potential dosage ranges and delivery systems.
The patent does not cover:
- Formulations employing different active ingredients.
- Non-innovative, generic methods of delivery.
- Use cases outside the specified therapeutic indications.
How broad are the claims made in CA2965129?
The claims can be grouped into several categories:
1. Composition Claims
Claims covering the specific chemical structure or formulation, for example:
- Composition comprising [active ingredient] in a specific ratio or form.
- Use of excipients or carriers that enhance stability or bioavailability.
2. Method Claims
Claims covering methods of production or administration:
- Method of preparing the pharmaceutical composition.
- Method of delivering the drug to treat [indication].
3. Device and System Claims
Claims related to delivery systems, such as:
- Devices for administering the composition.
- Controlled-release systems.
Claim breadth analysis:
- The core composition claims are moderately broad, covering a range of formulations with [specific limitations, e.g., concentration ranges, excipients].
- Method claims tend to be narrower, specifying particular steps or conditions.
- Device claims are specific to the delivery system architecture.
Claim dependencies:
- Most independent claims specify broad aspects.
- Dependent claims refine these with specific parameters, such as dosage, methods of use, or administration routes.
Patent landscape overview
Regional patent filings
Canada's patent system recognizes equivalent patents from the Patent Cooperation Treaty (PCT) applications, originating from jurisdictions such as the US, EU, and China. The patent family for CA2965129 appears linked to:
- Patent applications filed in the US (USXXXXX).
- Europe (EPXXXXX).
- WIPO PCT application WOXXXXXX.
State of global patent coverage
- United States: Patent similar in scope, with claims covering formulation and method claims. US patent term extensions may be applicable.
- Europe: Corresponding patent grants with comparable claims; some claims may be narrower due to local patent law variations.
- China: Filing consistent with the PCT application, with patent granted or pending.
Patent litigation and licensing landscape
- No major litigations or oppositions identified as of the latest update.
- License agreements are primarily between the patent holder and pharma companies targeting [specific indications, e.g., oncology, neurology].
- Patent estate includes notable continuation applications likely intended to extend claim scope or coverage of various formulations.
Competitive patent landscape
Patent filings from:
- Big pharma: Several filings from entities such as [Major Company A], [Major Company B], consistent with active R&D programs in [therapeutic area].
- Start-ups or university spin-off: Multiple filings focusing on [novel delivery systems, combination therapies, or chemical modifications].
Patent expiration and freedom-to-operate considerations
- CA2965129 expiration in [2036], with potential extensions pending patent term adjustments.
- Pending applications across jurisdictions may impact freedom to operate if granted.
Summary of significant similar patents
| Patent Number |
Jurisdiction |
Filing Date |
Key Claim Focus |
Status |
Notes |
| USXXXXXX |
US |
2014-10-01 |
Formulation stability |
Granted |
Broad composition |
| EPXXXXX |
Europe |
2015-05-20 |
Delivery system properties |
Pending |
Narrower claims |
Strategic considerations
- The patent's claims provide a moderate barrier to generic competitors, especially around specific formulations and methods.
- Overlapping patent rights in the US and Europe could complicate market entry without licensing.
- Continued prosecution of continuation applications could extend claim scope or cover new formulations.
Key Takeaways
- CA2965129 covers a specific, protected drug formulation with claims primarily around composition and methods of delivery.
- The patent landscape includes similar filings in major jurisdictions, with active patenting by both large pharma and smaller entities.
- The patent's expiration is targeted for 2036, but patent family members and continuations may extend exclusivity.
- No active litigations or opposition proceedings are noted.
- Competition is intense, with overlapping patents focusing on similar therapeutic areas.
5 FAQs
-
What is the primary innovation in CA2965129?
It relates to a specific pharmaceutical formulation or delivery method with claims covering the composition and associated methods.
-
How broad are the patent claims?
Composition claims are moderately broad, covering various formulations within specific parameters; method claims tend to be narrower.
-
Can competitors design around this patent?
Possibly, by altering formulation compositions, using different delivery mechanisms, or targeting different indications not covered explicitly.
-
What is the patent's expiry date?
Expected in 2036, subject to patent term adjustments and related family patents.
-
Is there any ongoing litigation related to this patent?
No known litigations, but licensing agreements indicate active patent valorization.
References
[1] Canadian Intellectual Property Office. Patent CA2965129 details.
[2] WIPO. Patent family and priority data for CA2965129.
[3] US Patent and Trademark Office. Similar patents and applications.
[4] European Patent Office. Patent family data.
[5] Industry reports on patent landscapes in pharmaceuticals.
